hotspot -WSS

hotspot

author：hotspot 2025-09-28 21:04:58 - browse：32

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

WSS

JPM 2024: Verve Therapeutics looks to mainstream genome editing

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

A new ‘biological computer' targets cancer while sparing healthy cells

New Medicare drug pricing powers could soon be upended in court

Health and fitness trackers are measuring the wrong things

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

New menopause drug shows promise in relief for hot flashes

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Drug repurposing or repositioning? The language matters

A new ‘biological computer' targets cancer while sparing healthy cells

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mystery swirls around US soldier who entered North Korea days ago, officials say

23andMe had bad news about my health. I wish a person had delivered it

Idaho abortion case may prompt more restrictions in other states

entertainment

New Medicare drug pricing powers could soon be upended in court

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Mystery swirls around US soldier who entered North Korea days ago, officials say

As JPM 2024 winds down, some health tech firms project optimism

Fauci’s Covid grilling leads GOP to weigh foreign research rules

explore

focus

hotspot

focus